DrugPatentWatch Database Preview
PYLARIFY Drug Patent Profile
Email this page to a colleague
Which patents cover Pylarify, and when can generic versions of Pylarify launch?
Pylarify is a drug marketed by Progenics Pharms Inc and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-eight patent family members in twenty-one countries.
The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Pylarify
Pylarify will be eligible for patent challenges on May 26, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 21, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for PYLARIFY
| International Patents: | 68 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in PYLARIFY? | PYLARIFY excipients list |
| DailyMed Link: | PYLARIFY at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for PYLARIFY
Generic Entry Date for PYLARIFY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for PYLARIFY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PYLARIFY
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5806765 | ⤷ Try it Free |
| Japan | 5936659 | ⤷ Try it Free |
| Hungary | E034027 | ⤷ Try it Free |
| Cyprus | 1116610 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
